Japanese Lung Cancer Registry Study First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002
Japanese Lung Cancer Registry Study First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002
复制标题
DOI：
10.1097/jto.0b013e3181e452b9
复制
发表时间：
2010-09-01
影响因子：
20.4
通讯作者：
Fujii, Yoshitaka
中科院分区：
文献类型：
--
作者：
Sawabata, Noriyoshi;Asamura, Hisao;Fujii, Yoshitaka
目的：研究日本肺癌登记研究前瞻性纳入的肺癌患者的预后。方法：纳入2002年新诊断为肺癌的患者，进行两次随访调查。对14695例（79%）患者的最终随访资料进行预后分析。根据国际抗癌联盟第六版肿瘤、淋巴结、转移分类（2002年）确定临床分期。结果：平均年龄671岁（范围18 ~ 89岁），男性10194例（69.3%），女性4315例（29.7%），最常见的组织学为腺癌（8325例，56.7%），其次为鳞状细胞癌（3778例，26%）和小细胞癌（1345例，9.2%），临床分期分布如下：IA， 4245例（29.3%），IB， 2248例（14.5%），IIA。208例（14.4%），918例（6.3%），1700例（11.8%）。所有患者的5年生存率为44.3%，非小细胞肺癌患者为46.8%，小细胞肺癌患者为14.7%。根据非小细胞肺癌和小细胞肺癌的临床分期，IA期的5年生存率分别为794和52.7%，IB期为569和39.3%，IA期为49.0和31.7%。IIB组分别为423和29.9%，IIIA组为309和17.2%，IIIB组为167和12.4%，IV组为58和3.8%。结论：日本注册研究的大队列分析发现，分期特异性预后在与其他报道相似的范围内，本文的数据应为日本未来的临床试验提供重要参考
Purpose: To investigate prognoses of lung cancer patients prospectively enrolled in the Japan Lung Cancer Registry StudyMethods: Patients newly diagnosed as having lung cancer exclusively in 2002 were enrolled Follow-up surveys were performed twice. in 2004 and 2009, and the final follow-up data with prognoses were analyzed for 14,695 patients (79%) Clinical stages were defined according to the sixth edition of the International Union Against Cancer-tumor, node, metastasis classification (2002).Results: The mean age was 67 1 years (range, 18-89 years), and there were 10,194 men (69 3%) and 4315 women (29 7%) The most frequent histology was adenocarcinoma (n = 8325, 56 7%), followed by squamous cell carcinoma (a = 3778, 26%) and small cell carcinoma (a = 1345, 9 2%) The distribution of clinical stages was as follows IA, 4245 cases (29 3%), IB. 2248 (14 5%), IIA. 208 (1 4%), IIB, 918 (6 3%), IIIA, 1700 (11 8%). IIIB, 2110 (16 3%), and IV, 3037 (21 0%) The 5-year survival rates were 44.3% for all patients, 46 8% for those with non-small cell lung cancer, and 14 7% for those with small cell lung cancer According to the clinical stage of non-small cell lung cancer and small cell lung cancer, the 5-year survival rates were 794 and 52 7% for stage IA, 569 and 39 3% for IB, 49.0 and 31 7% for IA. 423 and 29.9% for IIB, 309 and 17 2% for IIIA, 167 and 12 4% for IIIB, and 58 and 3 8% for IV, respectivelyConclusion: Analysis of a large cohort in the Japanese registry study found that stage-specific prognosis was within a range similar to other reports The data presented should provide an important reference for future clinical trials in Japan